Objective-S100A12 and fibroblast growth factor 23 are biomarkers of cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD). We tested the hypothesis that human S100/calgranulin would accelerate cardiovascular disease in mice subjected to CKD. Approach and Results-A bacterial artificial chromosome of the human S100/calgranulin gene cluster containing the genes and regulatory elements for S100A8, S100A9, and S100A12 was expressed in C57BL/6J mouse (hBAC-S100) to generate a novel humanized mouse model. CKD was induced by ureteral ligation, and hBAC-S100 mice and wild-type mice were studied after 10 weeks of chronic uremia. hBAC-S100 mice with CKD showed increased fibroblast growth factor 23 in the hearts, left ventricular hypertrophy, diastolic dysfunction, focal cartilaginous metaplasia, and calcification of the mitral and aortic valve annulus together with aortic valve sclerosis. This phenotype was not observed in wild-type mice with CKD or in hBAC-S100 mice lacking the receptor for advanced glycation end products with CKD, suggesting that the inflammatory milieu mediated by S100/receptor for advanced glycation end products promotes pathological cardiac hypertrophy in CKD. In vitro, inflammatory stimuli including interleukin-6, tumor necrosis factor-α, lipopolysaccarides, or serum from hBAC-S100 mice upregulated fibroblast growth factor 23 mRNA and protein in primary murine neonatal and adult cardiac fibroblasts. Conclusions-Myeloid-derived human S100/calgranulin is associated with the development of cardiac hypertrophy and ectopic cardiac calcification in a receptor for advanced glycation end products-dependent manner in a mouse model of CKD. We speculate that fibroblast growth factor 23 produced by cardiac fibroblasts in response to cytokines may act in a paracrine manner to accelerate left ventricular hypertrophy and diastolic dysfunction in hBAC-S100 mice with CKD. (Arterioscler Thromb Vasc Biol. 2014;34:1399-1411 .) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
C hronic kidney disease (CKD) is a global health problem and is associated with accelerated cardiovascular disease, the leading cause of premature death among patients with CKD. 1 Several factors contribute to cardiovascular morbidity in CKD including oxidative stress, inflammation, dyslipidemia, hypertension, atherosclerosis, vascular calcification, and left ventricular (LV) dysfunction among others. Epidemiological studies in dialysis patients have identified serum S100A12 levels as a significant and independent determinant for carotid intimal-media thickness 2,3 and peripheral artery disease 4 and as a predictor for cardiovascular mortality. [5] [6] [7] The origin of the elevated S100A12 serum levels in patients with CKD and other chronic or acute inflammatory disease is not clear, but leucocytes are a possible source because these cells are the major producer of S100A12, and the molecule is released from dying leucocytes or on activation. This is supported by recent findings by Hara et al 8 demonstrating a strong correlation between S100A12 mRNA in leucocytes and serum S100A12 concentrations in uremic CKD patients. S100/calgranulin binds to and activates the receptor for advanced glycation end products (RAGE) and thereby promotes vascular inflammation. [9] [10] [11] This suggests that S100A12 could directly participate in cardiovascular disease, rather than just serve as a biomarker of inflammation. S100A12 and homolog S100A8/9 (also known as S100/ calgranulins) belong to the family of EF-hand calciumbinding proteins and are endogenously expressed in myeloid cells, particularly in neutrophil granulocytes where they comprise 5% and 40% of cytosolic proteins, respectively. 12, 13 Accordingly, elevated serum concentrations of S100/calgranulins are associated with acute and chronic inflammatory diseases. In addition to their endogenous expression in myeloid cells, S100/calgranulins are induced in human vascular smooth muscle under pathological conditions, such as atherosclerosis, 14 coronary artery plaque rupture, 15 ischemia, 16 aortic aneurysms and dissections, 17 and in murine smooth muscle in response to endothelial injury. 18 Recently, our laboratory demonstrated in mice engineered to express human S100A12, driven by the smooth muscle 22-α promoter, osteochondrocytic reprogramming of vascular smooth muscle cells with activation of osteoblastic genes leading to accelerated atherosclerosis and vascular calcification when exposed to hyperlipidemia, 19 or when exposed to surgically induced CKD. 20 The present study was designed to test the hypothesis that elevated levels of S100/calgranulin in myeloid cells and serum in mice with CKD would accelerate pathological cardiac remodeling and to identify potential underlying mechanisms. To test this hypothesis, we exploited the fact that S100A12 is not present in mice 21 and generated transgenic mice expressing human S100/calgranulin proteins in cells and tissues similar to the expression pattern in humans, by using a bacterial artificial chromosome containing 60 kb of human DNA of the S100 gene cluster containing the genes and regulatory DNA for S100A8, S100A12, and S100A9 (hBAC-S100 mice). hBAC-S100 and wild-type (WT) littermate mice were subjected to a protocol of renal injury, and their hearts were studied 10 weeks after exposure to elevated blood urea nitrogen (BUN). We found cardiac hypertrophy and diastolic dysfunction together with focal cartilaginous metaplasia and calcification in the fibroblast-rich annulus of the mitral and aortic valves and thickening of the aortic valve leaflets in hBAC-S100 mice with CKD, but not in WT mice with CKD. We identified S100/calgranulin-mediated inflammation, at least in part, as an underlying mechanism of this pathological cardiac remodeling, because hBAC-S100 mice lacking RAGE had attenuated systemic inflammation and did not develop pathological cardiac remodeling when exposed to the same degree of CKD.
Our data presented here implicate S100/RAGE for the first time as an accelerating factor for the development of cardiac hypertrophy and diastolic dysfunction in CKD. Our data suggest that enhanced fibroblast growth factor 23 (FGF23) secretion in cardiac fibrous tissue may promote processes leading to cardiac hypertrophy and diastolic dysfunction.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Enhanced Inflammation in hBAC-S100 Mice
Transgenic mice were generated by using a bacterial artificial chromosome containing 60 kb of human DNA of the S100 gene cluster containing only the genes for human S100A8, S100A9, and S100A12, and regulatory DNA. We found transgenic expression of human S100A12 protein in myeloid blood cells ( Figure 1A ) and in the serum of hBAC-S100 mice ( Figure 1B ). S100A12 is coexpressed in myeloid cells with endogenous murine S100A8, and as expected, S100A12 protein was not detected in myeloid cells and in the serum of WT mice. 21 Interestingly, despite expression on hS100A8/9 mRNA in peripheral blood leucocytes, serum concentration of S100A8/9 was similar in both groups, even when measured using antibodies that recognize both murine and human S100A8/9. S100A12 mRNA was detected at high levels in white blood cells, bone marrow, and spleen and at much lower expression levels in all other organs tested including the heart, aorta, kidney, skin, lung, and muscle. S100A12 mRNA was not detected in cultured cardiac fibroblasts and cardiomyocytes harvested from hBAC-S100 hearts and at low level in whole heart tissue when normalized to the abundant expression of myosin heavy chain 7 (0.00066 and 1, respectively; Figure 1C ). Clinically, transgenic mice appear and develop normally and are fertile. There was no difference in the counts for leucocytes, segmented neutrophils, lymphocytes, platelets, and hemoglobin, as well as serum aspartate aminotransferase, alanine aminotransferase, creatinine, and total serum cholesterol (data not shown). Differential gene expression in white blood cells from 6-week-old animals was first tested by microarray (IlluminaWG-6v2; Table IA -IC in the online-only Data Supplement), and selected genes were verified by quantitative reverse transcriptase polymerase chain reaction. As shown in Figure 1D , we found a 3-to 45-fold increase in gene expression associated with inflammation or neutrophil activation, including lipopolysaccaride (LPS)binding protein, myeloperoxidase, neutrophil lactoferrin, vascular cell adhesion molecule 1, neutrophil proteinase 4, CD177, neutrophil gelatinase-associated lipocalin, bone marrow proteoglycan 2, CCAAT/enhancer-binding protein ε, cathepsin G, and chitinase 3-like 3, which was attenuated in hBAC-S100 mice lacking RAGE ( Figure 1E ). Consistent with prior findings, 9, 22, 23 overexpression of S100/calgranulin led to a sustained inflammatory milieu with increased interleukin-6 (IL-6) and IL-22 ( Figure 1F and 1G), which was abolished in hBAC-S100 mice lacking RAGE ( Figure 1H ). 
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Model of Surgically Induced CKD
Ten-week-old hBAC-S100 mice and WT littermate mice were subjected to reversible right ureteral obstruction for 6 days, followed by irreversible left ureteral obstruction to induce a moderate degree of CKD (Figure 2A ). 20 Sham-operated mice underwent repeated anesthesia and laparotomy with inspection of the ureter. Serum BUN was elevated ≈2.5-fold in mice after left ureteral obstruction compared with shamoperated mice (P<0.0001), and there was no significant difference in BUN among different groups of mice undergoing ureteral obstruction ( Figure 2B ). In parallel, serum creatinine was significantly elevated in all mice with CKD compared with sham (0.37±0.12 versus 0.14±0.09 mg/dL; P<0.001).
Moreover, calcium and phosphorus were not different between hBAC-S100 and WT mice undergoing ureteral ligation, indicating that S100/calgranulin had no direct effect on the severity of CKD or degree of hyperphosphatemia in this model. Furthermore, there were no differences in the degree of tubular atrophy, interstitial fibrosis, and interstitial inflammation on light microscopy of the right kidney, indicating that Myh7 A12 Myh7 A12 CTGF A12 CD68 A12 CD68 A12 CD68 A12 Figure 1 . Transgenic expression of human S100/calgranulin in myeloid cells is associated with inflammation. A, Transgenic expression of a bacterial artificial chromosome containing the human S100/calgranulin genes (hBAC-S100) upregulates protein expression of S100A12 in myeloid blood cells (red-stained cells on immunofluorescent microscopy inset b) and not in wild-type (WT) peripheral blood cells (inset e). B, S100A12 is increased in serum of hBAC-S100 mice and not detectable in WT serum (*P<0.001). C, Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for S100A12 mRNA normalized to β-actin and expressed as fold change compared with the expression of a tissue-specific abundant gene (myosin heavy chain 7 [Myh7] for heart tissue and isolated cardiac myocytes; connective tissue growth factor [CTGF] for isolated cardiac fibroblasts; CD68 for peripheral blood leucocytes, spleen, and bone marrow). D and E, qRT-PCR from peripheral blood cDNA of 6-week-old WT and hBAC-S100 littermate mice with intact receptor for advanced glycation end products (RAGE) signaling (D) and from 6-week-old WT and hBAC-S100 littermate mice with deleted RAGE signaling (RAGE knockout [KO]; E) for lipopolysaccaride-binding protein (LBP), myeloperoxidase (MPO), neutrophil lactoferrin (LTF), vascular cell adhesion molecule 1 (VCAM1), neutrophil proteinase 3 (PRTN3), human neutrophil alloantigen 2a (CD177), neutrophil gelatinase-associated lipocalin (LCN2), proteoglycan 2, bone marrow (PRG2), CCAAT/enhancer-binding protein ε (C/EBPE), cathepsin G (CTSG), and chitinase 3-like 3 (CHI3l3). Serum interleukin-6 (IL-6) and IL-22 are increased in hBAC-S100 mice with intact RAGE (F and G) and attenuated IL-6 and IL-22 in mice lacking RAGE (WT and hBAC-S100) despite expression of S100A12 in hBAC/S100-RAGE KO mice (H; *P<0.03).
transgenic expression of S100/calgranulin had no major effect on the response to reversible right ureteral ligation injury ( Figure 2C and 2D). The repeated surgeries were well tolerated, and there were no significant differences in body weight across the 4 groups of mice (data not shown). As previously reported in other mouse models of hydronephrosis, 24 systolic and diastolic blood pressure levels were significantly elevated in mice with CKD compared with sham-operated mice, although there was no significant difference between hBAC-S100 and WT mice within their respective groups ( Figure 2E ). Similar to previous findings of elevated serum FGF23 after 5/6 nephrectomy, 25 we found significantly elevated FGF23 in the serum of mice after ureter ligation. FGF23 was similar between sham-operated WT and hBAC-S100 mice and significantly increased in mice with CKD without any significant difference between hBAC-S100 and WT-CKD mice within their respective groups ( Figure 2F ). This suggests that S100/calgranulin, at least in WT-sham S100-sham WT-CKD S100-CKD * * * * WT-sham S100-sham WT-CKD S100-CKD WT sham S100 sham WT CKD S100 CKD human serum * * p=0.04 BUN mg/dl CKD sham * * * * WT-sham S100-sham WT-CKD S100-CKD WT/RAGE-/-CKD S100/RAGE-/-CKD RUO RRUO LUO time post LUO (days) 7 21 53 81 S100-CKD WT-CKD
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Fibrosis/tubular atrophy Inflammation WTsham S100sham WT-CKD S100-CKD WT-CKD S100-CKD RAGE+/+ RAGE-/-histological score (kidney tissue) blood pressure (mmHg) serum FGF23 (pg/ml) serum S100A12 (ng/ml) Model of chronic kidney disease (CKD) in human bacterial artificial chromosome (containing S100 genes; hBAC-S100) and wild-type (WT) littermate mice. A, Reversible surgical ligation of the right ureter followed by irreversible ligation of the left ureter. B, Blood urea nitrogen (BUN) was measured in the serum at various time points until euthanatized as an indicator for developing CKD after reversible right ureter obstruction (RUO) for 6 days, followed by release of RUO (RRUO), followed 7 days later by irreversible left ureter obstruction (LUO; *P=0.001 vs sham). C and D, Representative hematoxylin and eosin-stained slides of the right kidney were scored for interstitial fibrosis with tubular atrophy and for interstitial inflammation using scores of 0 to 3 for semiquantitative assessment with 0 indicating <5%; 1, 6% to 25%; 2, 26% to 50%, and 3, >50% involvement. There was no difference in renal pathology among the 4 CKD groups. Bar, 10 μm. E, Systolic and diastolic blood pressure were measured in the tail artery (*P=0.04 vs respective sham group). Serum fibroblast growth factor 23 (FGF23; F) and S100A12 (G) were measured by ELISA (*P=0.01 vs respective sham group). All values are mean±SEM. n>20 mice per group. RAGE indicates receptor for advanced glycation end products.
this animal model of CKD, does not independently contribute to elevated serum FGF23. In contrast, serum hS100A12 increased further in hBAC-S100 mice with CKD when compared with sham-operated hBAC-S100 mice (42±17 and 25±7 ng/mL, respectively; P=0.04; Figure 2G ), suggesting that the metabolic changes associated with CKD promote the release of S100A12 from myeloid cells. Moreover, the serum concentration of S100A12 in hBAC-S100 mice was comparable with concentration measured simultaneously in 10 human serum samples (mean, 28.2±29 ng/mL), indicating that this novel transgenic hBAC-S100 mouse model is compatible to human physiology with regard to S100A12 expression.
S100/Calgranulin Accelerates LV Hypertrophy and Diastolic Dysfunction in CKD
To determine whether mice with increased serum concentration of S100/calgranulin would be more susceptible to pathological cardiac remodeling, we performed detailed in vivo cardiac echocardiography. As shown in Figure 3 , systolic LV function measured by fractional shortening was similar in all 4 groups ( Figure 3A and quantified in Figure 3D ). LV posterior wall thickness was similar between sham-operated mice but was significantly increased in hBAC-S100 mice with CKD compared with WT-CKD mice ( Figure 3A and quantified in Figure 3E ). Diastolic function measured by the ratio of early to atrial mitral flow was similar between sham-operated mice but significantly reduced in hBAC-S100 mice with CKD compared with WT-CKD mice ( Figure 3B and quantified in Figure  3F ). This suggests that hBAC-S100 mice challenged with CKD are more prone to develop LV hypertrophy (LVH) and abnormal diastolic function. Consistent with this finding, peak aortic valve velocity time integral was significantly increased in hBAC-S100 mice with CKD compared with WT-CKD mice, whereas it was similar between sham-operated mice ( Figure 3C and quantified in Figure 3G ). In contrast, mean aortic valve velocity time integral was similar between all 4 WT S100 WT S100 sham CKD p=0.03 sham WT S100 CKD WT S100 sham WT-sham S100-sham WT-CKD S100-CKD * H I WT hBAC-S100
sham CKD Heart/ body weight (mg/g) Figure 3 . Human bacterial artificial chromosome (containing S100 genes; hBAC-S100) mice with chronic kidney disease (CKD) develop left ventricular hypertrophy (LVH) and impaired diastolic function. A, M-mode Doppler for measurement of fractional shortening (FS; quantified in D) and left ventricular posterior wall thickness (LVPW; quantified in E). B, Continuous-wave Doppler over the mitral valve for early (E) and atrial (A) flow was measured to calculate E/A (quantified in F). C, Continuous-wave Doppler over the aortic valve was measured to calculate mean and peak aortic valve velocity timed integral (AoVTI; quantified in G). H, Representative gross pathology sections from the cardiac midchamber (hematoxylin and eosin stain, magnification, ×5; bar, 20 μm) demonstrate LVH, confirmed by (I) increased ratio of heart weight to body weight in hBAC-S100/CKD mice (*P=0.01 compared with wild type [WT]/CKD and S100/sham). All values are mean±SEM; n>20 mice per group.
groups, suggesting that the accelerated peak aortic flow in hBAC-S100 mice with CKD stems from increased LV force and mild aortic valve abnormalities, rather than obstructive aortic valve stenosis.
LVH in hBAC-S100/CKD mice was confirmed on necropsy, and representative cardiac sections of the midcavity are shown in Figure 3H . The absolute heart weight was significantly increased in hBAC-S100/CKD mice compared with WT/CKD mice (188±26 and 141±19 mg, respectively; P<0.04) and was also increased when indexed to body weight ( Figure 3I ). In contrast, sham-operated WT and hBAC-S100 mice had equal LV posterior wall thickness ( Figure 3E ) and similar heart weights (138±17 and 136±15 mg, respectively). This indicates that transgenic expression of S100/calgranulin in the absence of CKD is not sufficient to induce cardiac hypertrophy in mice aged ≤5 months.
Taken together, our data indicate that expression of human S100/calgranulin in mice challenged with CKD promotes LVH, abnormal diastolic function, and mildly accelerated peak flow across the aortic valve.
LVH and Diastolic Dysfunction in hBAC-S100/ CKD Mice Are Associated With Aortic Valve Sclerosis and Ectopic Cardiac Calcification
Next, we examined serial cardiac sections stained for hematoxylin and eosin, Masson trichrome, Verhoeff van Giessen, and Alizarin Red systematically from the apex through the ascending aorta. Hypertrophic cartilage cells and calcification foci were present in all hearts from hBAC-S100 mice with CKD, whereas this was almost completely absent in the hearts from the WT-CKD mice (Figure 4 ). The chondrocytic hypertrophy and calcification were most often located in the fibrous tissue of the mitral valve annulus and aortic valve annulus, and there was scant calcification of cardiomyocytes in the left or right ventricle. A representative histology of chondrocytic hypertrophy with calcification in the mitral valve annulus is shown in Figure 4A and that of the aortic valve annulus is shown in Figure 4B . Consistent with increased peak aortic valve velocity time integral on echocardiography, hBAC-S100 mice with CKD showed significantly thicker aortic valve leaflets but without overt calcification ( Figure 4B and 4E). Abnormal aortic valve thickness, chondrocytic hypertrophy, and calcification were absent in all age-matched hBAC-S100 and WT mice undergoing sham surgery, indicating that the metabolic milieu of CKD accelerates valvular pathology in S100/calgranulin transgenic mice.
However, hBAC-S100 mice aged 10 to 12 months also developed enhanced calcification visualized by Alizarin Red staining which was near absent in age-matched WT littermate mice ( Figure 4C) , indicating that the expression of hS100/calgranulin is sufficient to mediate hypertrophic cartilage cells and cardiac calcification even in the absence of CKD. Calcification was located in the aged hBAC-S100 mice mostly near the aortic valve annulus and occasionally on the leaflet tip (and infrequently at the mitral valve annulus), and a representative histology of a 10-month-old animal is shown in Figure 4C . Aortic valve thickness did not differ between 10-to 12-month-old hBAC-S100 and WT littermate mice, with both groups of aged mice having significantly thicker valves compared with their respective group of younger mice ( Figure 4E ).
hBAC-S100 Mice With CKD Have Increased Cardiac Expression of FGF23 and LVH
Because of the increased LV posterior wall thickness on in vivo echocardiography and confirmed LVH on necropsy in hBAC-S100 mice with CKD, we probed cardiac tissue for mRNA expression linked to cardiac hypertrophy and fibrosis. As expected, the expression of genes characteristic of LVH including myosin heavy chain-β, atrium natriuretic protein, transforming growth factor-β, and others was increased in hBAC-S100 hearts. Notably, FGF23 mRNA was 6.8-fold increased in hBAC-S100 mice with CKD compared with WT-CKD mice (P<0.001; Figure 5A ). Interestingly, serum concentration of FGF23 has recently emerged in several epidemiological studies as a biomarker predicting cardiovascular complications in patients with CKD, and a dose-dependent association between elevated FGF23 levels and a greater risk of major cardiovascular events and mortality has been demonstrated. 26, 27 A plausible explanation linking high FGF23 to greater cardiovascular risk was offered by studies in which elevated FGF23 was independently associated with LVH, and FGF23 was recently shown to directly induce cardiac hypertrophy in a paracrine manner. 25 Importantly, FGF23 protein was increased by 2.6-fold in the cardiac tissue lysates harvested from hBAC-S100/CKD mice ( Figure 5B ). FGF23 mRNA and protein were expressed at low levels in the heart of sham mice, and there was no significant difference between sham-operated WT and hBAC-S100 mice (data not shown).
Immunohistochemistry of serial cardiac sections demonstrated that FGF23 was expressed in valvular interstitial cells of hBAC-S100/CKD hearts ( Figure 5D ) and only minimally in cardiac fibrous tissue from WT/CKD ( Figure 5G ). Neonatal bone control tissue was used as positive control tissue ( Figure 5I ). The mRNA levels for cardiac expression of potential receptors for FGF23, namely FGFR1, FGFR2, FGFR3, FGFR4, and Klotho, were not different between hBAC-S100/ CKD and WT/CKD (data not shown).
Because mineralizing cells such as osteoblasts and chondroblasts are a principal source of FGF23, 28 we probed whether cardiac cells exposed to a milieu conducive to the promotion of chondroplastic metaplasia and enhanced mineralization would upregulate FGF23 in cardiac cells. As shown in Figure  I in the online-only Data Supplement, neonatal cardiac fibroblasts from WT hearts did not increase FGF23 mRNA in response to high-phosphate medium supplemented with either rS100A12 (1 μg/mL) or control BSA cultured for ≤20 days. As expected, genes important for the regulation of mineralization, including osteocalcin (bone γ-carboxyglutamic acid-containing protein), osteopontin, and matrix Gla protein, previously found at increased levels in calcific aortic valves of uremic animal models, 29, 30 increased in response to high-phosphate calcification medium. Although rS100A12 did not alter expression of FGF23, rS100A12 reduced significantly gene expression of osteopontin by 20% to 40% ( Figure  IC in the online-only Data Supplement). This suggests that S100/calgranulin may influence osteopontin regulation in cardiac fibroblasts, but may not directly promote expression of FGF23 in cardiac fibroblasts. We therefore hypothesized that systemic intermediary products in vivo might affect FGF23 expression in cardiac fibroblasts in hBAC-S100 mice subjected to CKD. We next studied whether cytokines might promote FGF23 expression in cardiac fibroblasts. As shown in Figure 5K , we found a robust and significant increase in FGF23 mRNA levels in response to cytokines in cardiac fibroblast and aortic smooth muscle cells when stimulated with low-dose cytokines including IL-6 (25 ng/mL), tumor necrosis factor-α (25 ng/mL), and LPS (25 ng/mL). In contrast, recombinant S100A12 (≤2 μg/mL) did not induce FGF23. However, stimulation with serum from hBAC-S100 mice upregulated FGF23 mRNA 2-to 3-fold compared with WT serum. Moreover, FGF23 protein was significantly elevated in the cell culture supernatant harvested from cardiac fibroblasts stimulated with either cytokines or serum from hBAC-S100 mice. Interestingly, cardiac fibroblasts lacking RAGE had the same robust upregulation of FGF23 protein in response to cytokines than cardiac fibroblasts with intact RAGE signaling ( Figure 5L) .
Taken together, our study shows that S100/calgranulin is sufficient to enhance pathological cardiac remodeling in mice with CKD with several pathological findings including LVH Figure 4 . Human bacterial artificial chromosome (containing S100 genes; hBAC-S100) mice with chronic kidney disease (CKD) develop ectopic cardiac calcification. Serial stained sections (A) of the mitral valve (MV) of hBAC-S100 (upper) and wild-type (WT) mice (lower) and (B) of the aortic valve of hBAC-S100 (upper) and WT mice (lower). Serial sections were stained for hematoxylin and eosin (H&E), Alizarin Red S staining calcium deposits in red color as marked by arrow, and Masson trichrome. P indicates pigment. Bar, 10 μm. C, Cardiac calcification developed spontaneously in 10-monthold hBAC-S100 mice (without CKD and on regular rodent chow diet) as shown by red color on Alizarin Red S-stained sections of the aortic valve and colocalizing to hypertrophic chondroblast-like cells (upper) and to calcification on the valve leaflet tip (lower). D, Red-colored calcification foci (shown by arrow) but not the black-colored pigment deposition (marked as P) on Alizarin Red S-stained serial sections (n=50-70 per heart) were counted from the apex to the ascending aorta. E, Quantification of the maximal aortic valve thickness of the 3 leaflets measured as depicted in B. All values are mean±SEM; n=10 mice per group. LA indicates left atrium; and LV, left ventricle. and impaired diastolic function, hypertrophic cartilage cells in the aortic and mitral valve annulus with spotty calcification in the valve annulus, increased aortic valve thickening with mild dysfunction, and increased cardiac expression of FGF23, likely in response to the enhanced inflammation present in hBAC-S100 mice.
Pathological Cardiac Remodeling in hBAC-S100 Mice With CKD Is Dependent on RAGE
To gain more insight into underlying molecular signaling cascades of S100/calgranulins resulting in pathological cardiac remodeling, we used mice lacking RAGE and tested whether RAGE is required to mediate these effects. hBAC-S100 mice Figure 5 . Human bacterial artificial chromosome (containing S100 genes) (hBAC-S100) mice with chronic kidney disease (CKD) develop left ventricular hypertrophy. A, Quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) in murine heart for genes associated with hypertrophy and fibrosis. B, Immunoblotting of cardiac tissue lysates for fibroblast growth factor 23 (FGF23) and β-actin and semiquantitative densitometry of bands. C to J, Serial sections of the aortic valve of hBAC-S100 (C-E) and wild-type (WT) control (F-H) stained with Alizarin Red (AR; C and F) and hematoxylin and eosin (H&E; E and H) show calcifying chondroblast-like cells (marked with an arrow) and expression of FGF23 in interstitial valve cells in hBAC-S100 mice (D) but not in WT mice (G). Nonimmune IgG was used as negative control (inset in D and G; J), and newborn murine WT bone tissue was used as positive control (I). Magnification, ×400; bar, 10 μm; P indicates pigment. K, Quantitative real-time RT-PCR in cultured primary murine cardiac fibroblasts (CFs) and aortic smooth muscle cells (ASMCs) for FGF23 mRNA after 6-hour stimulation with interleukin-6 (IL-6; 25 ng/mL), tumor necrosis factor-α (TNF-α; 25 ng/mL), lipopolysaccarides (LPS; 25 ng/mL), recombinant S100A12 (2 μg/mL), serum from hBAC-S100 mice (3%), or serum from WT mice (3%). L, FGF23 protein measured by ELISA in cell culture supernatant from primary neonatal cardiac fibroblast from WT/RAGE +/+ and WT/RAGE −/− mice after 24 hours stimulated with cytokines or mouse serum (*P<0.01 compared with control). ANP indicates atrium natriuretic protein; Col1a1, collagen type 1, α1; CTGF, connective tissue growth factor; RAGE, receptor for advanced glycation end products; Smad2, mothers against decapentaplegic homolog 2; TGF-β, transforming growth factor β; and β-MHC, myosin heavy chain β.
were bred with homozygote RAGE knockout mice, 31 and hBAC-S100/RAGE −/− and the WT/RAGE −/− littermate mice were subjected to the same protocol of surgically induced CKD. As shown in Figure 2B , BUN increased equally in hBAC-S100/RAGE −/− and WT/RAGE −/− mice subjected to CKD by ≈2.5-fold, and this was similar to the BUN levels achieved in mice with intact RAGE signaling. Moreover, serum creatinine (0.34±0.13 and 0.37±0.17; P=NS), serum phosphate (7.46±0.83 and 7.3±0.83; P=NS), and S100A12 (34±14 and 42±17 ng/mL; P=0.09) were similar between hBAC-S100/RAGE −/− mice with CKD and hBAC-S100/ RAGE +/+ mice with CKD. There was no difference in the semiquantitative scoring of kidney pathology on light microscopy between all the groups of mice with reversible ureteral ligation ( Figure 2C and 2D) . Moreover, systolic, diastolic, and mean blood pressure levels were similar between RAGE null mice with and without transgenic expression of human S100/calgranulin ( Figure 6A ), and the blood pressure levels were not different from CKD mice with intact RAGE signaling. Serum FGF23 was similar between the WT/RAGE −/− / CKD mice and hBAC-S100/RAGE −/− /CKD mice (425±31 and 526±28 pg/mL, respectively) but was significantly reduced in the WT/RAGE −/− /CKD mice compared with WT/ RAGE +/+ /CKD mice (425±31 and 630±48, respectively; P=0.03; Figure 6B ). In parallel with reduced IL-6 and IL-22 in hBAC-S100 mice lacking RAGE as shown in Figure 1H , hBAC-S100/RAGE −/− mice were protected from developing cardiac hypertrophy. The absolute heart weight (137±22 Figure 6 . Human bacterial artificial chromosome (containing S100 genes; hBAC-S100) mice with chronic kidney disease (CKD) and lacking receptor for advanced glycation end products (RAGE) are protected from cardiac hypertrophy and calcification. A, Systolic (SBP), diastolic (DBP), and mean arterial (MAP) blood pressure were measured in the tail artery. B, Serum fibroblast growth factor 23 (FGF23) was measured by ELISA. C, Indexed heart weight to body weight measured at euthanasia. D, Quantitative real-time reverse transcriptase polymerase chain reaction in murine hearts for selected genes associated with hypertrophy and fibrosis. E, Immunoblotting of cardiac tissue lysates for FGF23 and β-actin, including hBAC-S100/RAGE +/+ /CKD as positive control (left lane) and from mice lacking RAGE (lane 2-7) and semiquantitative densitometry of bands (F). G, E/A ratio of continuous-wave Doppler over the mitral valve for early (E) and atrial (A) flow is calculated as a measure of diastolic function. H, Quantification of red-colored calcification foci on Alizarin Red S-stained serial cardiac sections 200 μm apart was counted from the apex to the ascending aorta. ANP indicates atrium natriuretic protein; Col1a1, collagen type 1, α1; CTGF, connective tissue growth factor; Smad2, mothers against decapentaplegic homolog 2; TGF-β, transforming growth factor β; and β-MHC, myosin heavy chain β. and 134±19 mg, respectively; P=NS) or indexed heart weight was similar between WT/RAGE −/− and hBAC-S100/RAGE −/− ( Figure 6C ). Moreover, there was no difference between hBAC-S100/RAGE −/− and WT/RAGE −/− littermates in the gene expression of genes linked to hypertrophy and fibrosis, including FGF23, βMHC, ANP, TGFβ, Smad2, CTGF, and Col1a1 ( Figure 6D ). This was further confirmed by immunoblotting in cardiac tissue lysates, and FGF23 protein was equally low in WT/RAGE −/− and in hBAC-S100/RAGE −/− mice with CKD, in contrast to the increased FGF23 protein in cardiac lysates from hBAC-S100 mice with intact RAGE signaling ( Figure 6E and quantified in Figure 6F ). Finally, cardiac echocardiography in hBAC-S100/RAGE −/− /CKD and WT/RAGE −/− /CKD demonstrated normal LV systolic function (fractional shortening, 46±7% and 42±8%, respectively; P=NS), preserved diastolic function measured by continuous Doppler inflow over the mitral valve ( Figure 6G ), and normal mean and peak aortic valve velocity time integral (989±54 and 1021±47 mm/s; P=NS and 1589±97 and 1498±102 mm/s; P=NS, respectively). LV posterior wall thickness on M-mode echocardiography was similar in hBAC-S100/RAGE −/− /CKD (0.51±0.08 mm), WT/RAGE −/− /CKD (0.57±0.09 mm), and control WT/RAGE +/+ -sham mice (0.59±0.06 mm).
Together with normalization of inflammation and pathological cardiac hypertrophy in hBAC-S100/RAGE −/− mice, we found no significant focal cartilaginous metaplasia or cardiac calcification in mice lacking RAGE, and the scant calcification seen in the hBAC-S100/RAGE −/− mice was similar to WT mice ( Figure 6H ). This was accompanied by normal thickness of the aortic valve leaflets, and there was no difference between hBAC-S100/RAGE −/− mice with CKD, WT/RAGE −/− mice with CKD, and WT/RAGE + / + mice with CKD (61±7, 59±4, and 62±8 μm, respectively).
Taken together, our data demonstrate that S100/calgranulin promotes maladaptive cardiac remodeling in a RAGEdependent manner in metabolically challenged mice that mimic conditions of human CKD, that is, increased serum concentration of BUN and S100/calgranulin. S100/calgranulin promotes systemic inflammation, and our in vitro data suggest that upregulation of FGF23 in cardiac fibroblasts in response to cytokines might be a potential link between systemic inflammation and development of cardiac hypertrophy and diastolic dysfunction in vivo.
Discussion
LVH and diastolic dysfunction as well as vascular and cardiac calcification are commonly associated with CKD and contribute to the high incidence of heart failure and cardiovascular mortality observed among patients with CKD and end-stage renal failure. Although cardiac remodeling comprises a multifactorial and complex network in response to the metabolic and hemodynamic abnormalities associated with CKD, both serum S100A12 [5] [6] [7] and serum FGF23 25, 26, 32, 33 have been identified as powerful predictors of cardiovascular mortality in end-stage renal disease, suggesting a possible synergistic mechanism between S100A12 and FGF23. Our study, using a novel humanized mouse model with transgenic expression of hS100/calgranulin in myeloid cells and increased levels of circulating S100/calgranulin protein, demonstrates that S100/ calgranulin is sufficient to promote LVH and ectopic cardiac calcification in animals with CKD, and this process is dependent on RAGE, a pattern recognition receptor for multiple ligands including S100/calgranulins. Although hS100A8/9 mRNA was detected in myeloid cells, bone marrow, and spleen in hBAC-S100 mice, the serum concentration of S100A8/9, which likely is a composite of human and murine S100A8/9, was not increased compared with WT serum. We suspect that release of S100A8/9 from hematopoietic cells is regulated beyond mRNA levels.
In vivo, we demonstrate that transgenic expression of S100/ calgranulin leads to augmented expression of FGF23 in interstitial fibroblasts and the appearance of hypertrophic cartilage cells in the aortic and mitral valve annulus. It is tempting to speculate that the paracrine secretion of FGF23 from cardiac fibroblasts together with other factors mediates cardiac hypertrophy and diastolic dysfunction that was observed in mice with transgenic expression of human S100/calgranulin ( Figure 7) . A possible role for cardiac-derived FGF23 in mediating cardiac hypertrophy was previously suggested by a study demonstrating that injection of recombinant FGF23 directly into the myocardium (without detection of recombinant FGF23 in the blood circulation) caused LVH, which was abolished by the pan-FGF receptor inhibitor PD173074. 25 However, endogenous production of FGF23 within cardiac cells has not been reported to our knowledge. In our animal model, serum FGF23 was equally elevated in hBAC-S100 and WT mice with CKD, whereas cardiac FGF23 was increased only in the hearts of hBAC-S100 mice. The mechanism whereby FGF23 gene transcription and protein secretion are augmented in the hearts of hBAC-S100 mice with CKD likely represents a response to inflammation because several cytokines were capable to induce FGF23 in cardiac fibroblasts or aortic smooth muscle cells. FGF23 is mainly produced by osteoblasts and chondroblasts in mineralized tissues, 28 and recent studies indicated that alterations in matrix mineralization stimulate FGF23 in osteoblasts. 34 However, FGF23 regulation in vascular smooth muscle cell and fibroblast is largely unknown. Our data show that direct treatment of cardiac neonatal fibroblasts with S100A12 protein alone, or together with high-phosphate medium, failed to upregulate FGF23 in vitro, indicating other systemic processes mediated by S100/calgranulin. To our knowledge, this is the first study to report enhanced FGF23 secretion in cultured vascular cells in response to cytokines. Our hypothesis that FGF23 is induced in response to inflammatory signals in vivo is supported by a recent study by Pöss et al 35 demonstrating a 100-fold increase in serum FGF23 in patients with cardiogenic shock. Although cytokines were not reported in this study, we speculate that the cytokine storm commonly associated with cardiogenic shock may contribute to the severe increase in serum FGF23. We propose that FGF23 could be a link between chronic inflammation and LVH, a common cause of diastolic heart failure in patients with diabetes mellitus or CKD. Our study raises the hypothesis that release of growth factors such as FGF23 from activated cardiac fibroblasts in hBAC-S100/CKD hearts could facilitate pathological cardiac remodeling. Although FGF23 is commonly measured in serum and correlates positively with LVH in patients with CKD, future studies are needed to explore cardiac expression of FGF23 and whether this mediates LVH in a paracrine manner. Our in vitro data demonstrate cytokine-induced upregulation of FGF23 in cardiac fibroblasts, suggesting that cardiac-derived FGF23 could be a link between systemic inflammation and development of LVH and diastolic heart failure. Supported by recent findings that systemic treatment with pan-FGF receptor inhibitor PD173074 attenuated cardiac hypertrophy in 5/6 nephrectomy rats with CKD, 25 future experiments using cardiac-specific inhibition of FGF23 are needed to better understand the relationship of FGF23 and cardiac hypertrophy.
A recent epidemiological study in dialysis patients found a positive correlation of serum S100A12 with systemic inflammatory status and with abdominal aortic calcification, 3 but to our knowledge, it is not known whether serum S100A12 is a biomarker for cardiac calcification or LVH and whether this would occur independently of serum FGF23. In contrast, serum FGF23 is associated with LVH, but not associated with arterial calcification in patients with CKD, supporting the hypothesis that elevated serum concentrations of FGF23 in patients with CKD primarily affect the heart, but not the arterial vasculature. 36 RAGE was previously shown to mediate diabetic cardiomyopathy 37 and is implicated in cardiac remodeling in response to ischemic injury. 16, 38, 39 Our study expands these findings and demonstrates that RAGE-mediated systemic inflammation also mediates LVH with diastolic dysfunction and accelerates aortic valve thickening and sclerosis in an animal model engineered to mimic human disease, that is, increased serum S100A12 and uremia. An important role of systemic inflammation is supported by the finding that hBAC-S100/ RAGE null hearts lacked FGF23 expression (presumably attributable to the lack of systemic inflammation), whereas cultured primary cardiac fibroblasts from RAGE null mice had similar upregulation of FGF23 mRNA and protein levels in response to cytokines. However, future studies are needed to probe whether cardiac myocytes lacking RAGE have a normal hypertrophic response to FGF23 as recently shown for WT cardiac myocytes. 25 Although our data seem to implicate systemic inflammation with increased cytokines as an important mediator of pathological cardiac remodeling in hBAC-S100 mice, we cannot exclude the possibility of increased local inflammation mediated by the infiltration of S100/calgranulin-transgenic myeloid cells.
Systemic and local inflammation has been extensively implicated in the progression of calcific aortic valve disease (reviewed in Rajamannan et al 40 ) . Our previous work identified enhanced inflammation and oxidative stress in aortic smooth muscle with transgenic expression of hS100A12, leading to induction of osteoblast marker genes, including DMP1, Runx2, BMP2, and BGLAP, and thereby promoting a switch from normal smooth muscle cells to calcifying smooth muscle cells. 19, 41 Our newly developed mouse model with myeloidtargeted expression of hS100/calgranulin shows enhanced expression of genes regulating inflammation in myeloid cells in an RAGE-dependent manner, and we suggest that RAGEmediated activation of systemic inflammation could activate cardiac fibroblasts to switch to a chondroblast-like phenotype in vivo. This view is supported by studies in which ENPP1 null mice in combination with loss of RAGE developed less arterial calcification and intra-arterial chondrogenic differentiation compared with ENPP1 null mice with intact RAGE . Increased serum concentration of S100/ calgranulins in mice with CKD promotes systemic inflammation in a receptor for advanced glycation end products (RAGE)-dependent manner, and this is associated with cartilaginous metaplasia and calcification of the valve annulus. Importantly, systemic inflammation in vivo (and in cultured cardiac fibroblasts on treatment with cytokines) upregulates endogenous fibroblast growth factor 23 (FGF23) in cardiac fibroblasts, which may act in a paracrine manner to promote LVH and diastolic dysfunction. Elevated serum FGF23 has been previously associated with LVH, and recombinant FGF23 was shown to directly cause hypertrophy of cardiac myocytes in vitro and in vivo. 24 signaling, indicating an important role for RAGE as modifier of phosphate-mediated calcification. 42 Future research is needed to define detailed mechanisms of how S100/calgranulin promotes osteochondrocytic reprogramming of valvular interstitial fibroblasts. Our data suggest systemic inflammation in vivo, although other mechanisms, for example, enhanced susceptibility to attract and harbor circulating osteogenic precursor cells contributing to chondrocytic hyperplasia and annular calcification, 40, 43 or the possibility that S100/calgranulin promotes chondroplastic metaplasia of valve cells indirectly by inducing LVH with altered mechanical and hemodynamic forces leading to accelerated valve injury and paracrine signaling from interstitial valve cells, 44 cannot be excluded. Our finding of reduced osteopontin mRNA in cardiac fibroblasts in response to recombinant S100A12 protein is an unexpected finding, because cytokines, inflammation, and oxidative stress have been shown to increase osteopontin expression in vascular cells. 45, 46 This pleiotropic effect of S100A12 on osteopontin regulation needs to be further examined. We speculate that the known proinflammatory signaling of S100A12 in combination with a reduction in osteopontin level, an important inhibitor of vascular mineralization, may lead to important insights on the mechanisms of S100A12-mediated calcification of vascular and valvular cell. The calcification observed in hBAC-S100 mice challenged with CKD was grossly limited to aortic and mitral valve annulus, and we found only scant calcification in the medial layer of the aorta. Although at first these findings seem to be in conflict with earlier studies in which we reported enhanced medial calcification of the aorta in mice with smooth muscletargeted expression of human S100A12, 20 it does suggest that circulating S100/calgranulin protein has a lesser effect on aortic smooth muscle compared with the intracellular expression of S100A12 in smooth muscle either achieved by transgenic engineered cells 19, 20 or in response to injury such as associated with aortic dissection. 17 Taken together, our study provides mechanistic insights into how both biomarkers of increased cardiovascular mortality in CKD, that is, S100A12 and FGF23, could synergize to provide an environment where S100/RAGE-mediated inflammation promotes upregulation of cardiac-derived FGF23, LVH, and diastolic dysfunction together with chondrocytic hypertrophy of the mitral and aortic valve annulus with spotty cardiac calcification. RAGE and its ligands S100/calgranulin are suggested as potential therapeutic targets to attenuate pathological cardiac remodeling in CKD. RAGE was previously shown by our laboratory to initiate proinflammatory pathways on activation by S100A12, also known as extracellular RAGE-binding protein (EN-RAGE). 9 The presented data implicate for the first time that S100/RAGE is an accelerating factor for the development of cardiac hypertrophy and diastolic dysfunction in a murine model of CKD, and we hypothesize that enhanced FGF23 secretion in cardiac fibrous tissue may promote processes leading to hypertrophy and diastolic dysfunction.
